Social Media Ideas for Alks

Alkermes plc 2026 Q2 - Results - Earnings Call Presentation

Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000

The insider still has significant holdings in the company, signaling confidence.

AMLX Stock Soars as Amylyx GLP-1 Drug Succeeds in Late-Stage Trial

AlfaSigma

AlfaSigma Anonymous (not verified) Mon, 08/03/2026 - 21:27 field_thread_url https://cafepharma.com/boards/threads/alfasigma.645010/ boar...

ALPEK, S.A.B. de C.V. (ALPKF) Q2 2026 Earnings Call Transcript

Alkermes plc Q2 2026 Earnings Call Summary

Alkane Resources Ltd 2026 Q4 - Results - Earnings Call Presentation

Alaska Air Group, Inc. (ALK) Q2 2026 Earnings Call Transcript

Alumis crushed by midstage lupus flop but plots path to phase 3 for TYK2 inhibitor

A phase 2b lupus trial of Alumis’ envudeucitinib has missed its primary and secondary endpoints. But the biotech is still moving the TYK2 inhibitor into phase 3 in the autoimmune d...

Altimmune’s next-gen GLP-1 curbs heavy drinking in ‘unequivocal’ ph. 2 alcohol use disorder win

An experimental drug targeting both GLP-1 and glucagon receptors has curbed heavy drinking in a phase 2 trial, providing hope that the ubiquitous weight loss meds can be effectivel...

Amyloidosis Continues To Fight Back

Altimmune’s GLP-1 Drug Reduces Heavy Drinking in Alcohol Use Disorder Trial

Altimmune’s pemvidutide achieved a statistically significant reduction in heavy drinking days compared to a placebo in a Phase 2 trial. This peptide drug, which is designed to acti...

Alumis’ TYK2 drug fails in key lupus study

Though Alumis still sees a path forward in lupus, the result made its drug the latest TYK2 blocker to struggle in conditions beyond psoriasis and psoriatic arthritis. 

Astera Labs, Inc. (ALAB) Q2 2026 Earnings Call Transcript

Axsome Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation

Smooth Sailing: Definium’s LSD Voyage Hits Primary and Key Secondary Endpoints in GAD

This morning, Definium Therapeutics announced positive topline results from its Phase 3 study of LSD (DT120) for generalised anxiety disorder (GAD). It comes just two months after...

Broker’s Call: Alkem Laboratories (Buy)

Elara Securities

ALSO Holding AG 2026 Q2 - Results - Earnings Call Presentation

AtaiBeckley: 'Hold'; Eli Lilly Acquisition For $2.8 Billion Adds To Its Neuroscience Pipeline

StockWatch: Lilly’s Up-to-$3.8B Deal for AtaiBeckley a Good Trip for Psychedelic Drugs, Analysts and Investors Agree

Eli Lilly agreed to acquire AtaiBeckley for up to $3.8 billion—of which Lilly will pay $2.8 billion upfront. The deal, set to close in the third quarter, expands Lilly’s neuroscien...

Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M

Alkeus brought to late-stage testing a Stargardt disease therapy that former executive chairman and Vertex founder Josh Boger once called, “if it works, the most perfect drug I’ve...

Alnylam (ALNY) Q2 2026 Earnings Call Transcript

TTR franchise revenues topped $1 billion for first time as AMVUTTRA gains traction.

Rosen Law Firm Encourages Alarum Technologies Ltd. Investors to Inquire About Securities Class Action Investigation - AL...

NEW YORK, July 20, 2026 /PRNewswire/ --

<![CDATA[Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals for $450 Million ]]>